Back to Search
Start Over
High expression of INHBA is an adverse prognostic factor for de novo acute myeloid leukemia.
- Source :
-
Leukemia & Lymphoma . Jan2018, Vol. 59 Issue 1, p114-120. 7p. - Publication Year :
- 2018
-
Abstract
- Inhibin-β A (INHBA) is a ligand of the transforming growth factor β superfamily and associated with tumorigenesis and tumor progression in solid tumors. In this study, we investigated the expression levels and clinical significance ofINHBAin acute myeloid leukemia (AML). The results showed that high expression ofINHBAwas significantly correlated with elderly age (>60 years) (p = .038), adverse cytogenetic risks (p = .034), negativeNPM1mutation (p = .016), positiveFLT3internal tandem duplications (p = .011), and low hemoglobin levels (<60 g/dL) (p = .04). Patients with high levels ofINHBAhad poor responses to therapies as indicated by lower complete remission rate (p = .004), higher early death rate (p = .018), and shorter relapse-free survival (p = .04) and overall survival (p = .003). Moreover, multivariate analysis showed that high expression ofINHBAwas an independent adverse prognostic factor for AML. Taken together, our study suggested that high expression ofINHBAwas an adverse prognostic factor forde novoAML. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 10428194
- Volume :
- 59
- Issue :
- 1
- Database :
- Academic Search Index
- Journal :
- Leukemia & Lymphoma
- Publication Type :
- Academic Journal
- Accession number :
- 125435373
- Full Text :
- https://doi.org/10.1080/10428194.2017.1324157